Skip to main content
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · PHAT ISIN · US71722W1071 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country US United States of America
Listing US PHAT

About Phathom Pharmaceuticals, Inc.

https://www.phathompharma.com/

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for acid-related gastrointestinal (GI) diseases. The company's primary efforts are centered on advancing its lead product candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB). This therapeutic is developed for a range of indications, including the treatment of erosive esophagitis, Helicobacter pylori (H. pylori) infection, and non-erosive reflux disease. Phathom aims to transform the treatment landscape for these conditions by addressing unmet medical needs and improving patient outcomes with innovative therapeutic options.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 80% confidence The document is a Form 8-K reporting the submission of matters to a vote of security holders at the 2026 Annual Meeting and provides detailed vote tallies for director elections, auditor ratification, and say-on-pay. This corresponds to ‘Declaration of Voting Results & Voting Rights Announcements’ (Code: DVA).
2026-05-21 English
10-Q - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-30 English
8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 30, 2026, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2026. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain the financial results but only announces their release. The length is 3495 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the earnings release) rather than the report itself. Therefore, the correct classification is Earnings Release (ER).
2026-04-30 English
ARS - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
Annual Report
2026-04-07 English
DEF 14A - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
Proxy Solicitation & Information Statement
2026-04-07 English
S-8 - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
Regulatory Filings
2026-03-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.